Renamed Lipoxen turns to Russia to derisk biotech development
This article was originally published in Scrip
"We want to derisk our approach to biotech drug discovery." So says Scott Maguire, CEO of the UK firm formerly known as Lipoxen. The company has just undergone a complicated series of transactions and manoeuvres aimed at taking advantage of the Russian government's interest in investing in biotech. The company has established a business model that enables it to launch its products early into Russia or India before deciding which ones to develop further for North American and European markets.
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.